Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.25
Bid: 44.00
Ask: 45.20
Change: 0.35 (0.79%)
Spread: 1.20 (2.727%)
Open: 45.35
High: 45.95
Low: 45.25
Prev. Close: 44.25
NCYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

R&D and UK operational update

23 Apr 2021 07:00

RNS Number : 3778W
Novacyt S.A.
23 April 2021
 

Novacyt S.A.

 

("Novacyt", the "Company" or the "Group")

 

R&D and UK operational update

 

Paris, France and Camberley, UK - 23 April 2021 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on the progress of its near-term COVID-19 research and development (R&D) programmes to address rapidly evolving testing demands, particularly as SARS-CoV-2 continues to mutate around the world. Novacyt also provides an update on its UK operations.

 

R&D highlights

· Expansion of PathFlow® lateral flow test (LFT) portfolio with COVID-19 tests

o Launch of LFT to detect SARS-CoV-2 IgG antibodies

o Development of LFT to detect and differentiate between SARS-CoV-2 IgG antibodies, launch expected Q3 2021

o Development of LFT to detect antigens for SARS-CoV-2, launch expected by end of Q2 2021

· Expansion of genesig® COVID-19 polymerase chain reaction (PCR) portfolio

o Launch of CE Mark three-gene target PCR test

· Expansion of PROmate™ COVID-19 PCR portfolio for workflow efficiency in a near-to-patient setting

o Development of two-gene target test, launch expected May 2021

o Launch of test to identify a key mutation, E484K, found in all current variants of concern (VOC)

· Expansion of SNPsig® COVID-19 PCR genotyping portfolio to detect SARS-CoV-2 variants

o Launch of CE Mark VariPLEX™ assay panel to detect multiple variants

o Development of test to detect a variant originally identified in India, launch expected week commencing 26 April 2021

 

UK operational highlights

· Expansion of UK commercial infrastructure

· Inclusion in Public Health England (PHE) National Framework Agreement

 

Graham Mullis, Chief Executive Officer of Novacyt, commented:

"The continued development and expansion of our COVID-19 portfolio demonstrates Novacyt's ability to match the rapid evolution of SARS-CoV-2 with real-time bioinformatics surveillance and accelerated product development. We remain committed to identifying patient needs and overcoming healthcare challenges today and in the years ahead as we continue to strengthen our position as a leading innovator in diagnostic testing.

 

"We are also pleased to be included in the PHE national framework, which allows PHE and NHS hospitals to purchase our accredited products without the need for direct contract awards. We look forward to the opportunity to expand our support of diagnostic testing in the UK through our established infrastructure and building a long-term future in this important market, as well as in international markets as we continue to invest in our direct commercial operations."

 

Expansion of the PathFlow® LFT portfolio

 

PathFlow® SARS-CoV-2 IgG is a professional use LFT for the detection of SARS-CoV-2 IgG antibodies, launched as a CE-IVD on 31 March 2021. The test provides a rapid turnaround time of results from ten minutes and has demonstrated sensitivity of 98% and specificity of 99% in validation studies.

 

PathFlow® SARS-CoV-2 SMART IgG is a next generation LFT to detect and, importantly, differentiate between IgG antibodies. The test is expected to assist clinicians in understanding the impact of immunisation programmes, as well as the levels of immunity derived from infection by the virus. The Company now expects to launch this test as a CE-IVD in Q3 2021.

 

PathFlow® SARS-CoV-2 Antigen is a professional and home use LFT for the detection of SARS-CoV-2 antigens using non-invasive anterior nasal swab samples to provide a result in approximately 15 minutes. Novacyt has been working with a partner to develop this test, which is able to detect the virus regardless of current known mutations. The Company intends to launch the test as CE-IVD before the end of Q2 2021 and expects it to complement Novacyt's established position in COVID-19 PCR testing. As the market for COVID-19 testing continues to develop, the Directors believe this product could add significant revenues for Novacyt.

 

Expansion of the genesig® COVID-19 PCR portfolio

Following an emerging need in some countries, Novacyt has launched a CE-IVD genesig® COVID-19 three-gene target test for use with nasopharyngeal, oropharyngeal and saliva sample types. This key extension to the genesig® COVID-19 portfolio, alongside the one-gene and two-gene tests, is expected to be critical for use in airport test and release programmes to and from certain countries.

 

Expansion of the PROmate™ PCR portfolio

PROmate™ remains the only direct-to-PCR assay approved by the UK's Technology Validation Group and enables near-to-patient testing with results in under 90 minutes. The current CE-IVD PROmate™ COVID-19 test identifies the SARS-CoV-2 ORF1ab gene. Due to an emerging need in some countries, the Company expects to launch a second CE-IVD PROmate™ COVID-19 test in May 2021 to identify both the SARS-CoV-2 ORF1ab gene and M gene.

 

In addition, Novacyt has launched PROmate™ SARS-CoV-2 E484K, a research-use-only (RUO) test to identify this key mutation, with a CE-IVD planned subject to demand. E484K is a mutation found in all current VOC and has been associated with immune evasion and reduction of vaccine efficacy.

 

Expansion of the SNPsig® PCR genotyping portfolio

In addition to Novacyt's recently launched CE-IVD assay panel, VariPLEX™, the Company has eight RUO assays, which it believes is the most complete variant detection portfolio currently available to address the globally prevalent variants of SARS-CoV-2.

 

An RUO assay to detect a new variant originally identified in India is expected to be launched in the next week and reinforces Novacyt's leadership in responding to an urgent public health need and market requirements. (Full detail on the SNPsig® portfolio can be found below.)

 

UK operational update

Novacyt has invested significantly in supporting the UK market during the past 12 months and now has over 50 field specialists servicing the NHS across England, Wales, Scotland and Northern Ireland. In addition, Primerdesign and Microgen Bioproducts, Novacyt's wholly owned subsidiaries, have been included in the National Microbiology Framework for Diagnostic Goods and Services (Lot 1) published by PHE for a full range of clinical products, including tests within the Company's accredited portfolio.

 

The successful inclusion of Primerdesign and Microgen Bioproducts in the PHE National Framework Agreement, coupled with the Company's investment in its commercial infrastructure to deliver new products and establish a direct sales force, means Novacyt is well positioned to develop a long-term commercial position in the UK market.

 

- End -

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer

James McCarthy, Chief Financial Officer

+44 (0)1276 600081

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black

+44 (0)20 7260 1000

 

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw / Mary Whittow

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / alex.shaw@fticonsulting.com / mary.whittow@fticonsulting.com / Novacyt.group@fticonsulting.com 

 

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

arnaud.decheffontaines@fticonsulting.com

 

About the SNPsig® portfolio

The table below contains details on Novacyt's SNPsig® portfolio of products, which have been launched to date or are due to launch imminently. Novacyt's bioinformatics surveillance group remains highly vigilant and, as significant new mutations are identified, these will be added to the SNPsig® portfolio.

 

Assay Type

Detection Profile

SNPsig® VariPLEX™ SARS-CoV-2

20I/501Y.V1, 20H/501Y.V2, 20J/501Y.V3, 20C/S.452R, N501Y, E484K

SNPsig® SARS-CoV-2 (20I/501Y.V1)

20I/501Y.V1 (UK)

SNPsig® SARS-CoV-2 (20H/501Y.V2)

20H/501Y.V2 (SA)

SNPsig® SARS-CoV-2 (20J/501Y.V3)

20J/501Y.V3 (Brazil)

SNPsig® SARS-CoV-2 (20B/S.484K)

20B/S.484K (Brazil)

SNPsig® SARS-CoV-2 (N501Y)

Variants with the N501Y mutation (UK, SA & Brazil)

SNPsig® SARS-CoV-2 (E484K)

Variants with the E484K mutation

SNPsig® SARS-CoV-2 (L452R)

Variants with the L452R mutation

SNPsig® SARS-CoV-2 (VUI-21APR-01) *

VUI-21APR-01 (India)

SNPsig® SARS-CoV-2 (VUI-21MAR-02) *

VUI-21MAR-02 (Brazil)

*in development

 

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly offers microbiology, haematology and serology products with a focus in respiratory and transplantation markets.

 

For more information please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDUUVARAKUSUUR
Date   Source Headline
1st Mar 202412:30 pmRNSLiquidity Agreement and Total Voting Rights
6th Feb 20247:00 amRNSUpdate on Taiwanese divestment
1st Feb 20241:00 pmRNSLiquidity Agreement and Total Voting Rights
25th Jan 20247:00 amRNSTrading update
3rd Jan 202411:00 amRNSLiquidity Agreement and Total Voting Rights
2nd Jan 20247:00 amRNSAppointment of CFO
21st Dec 20237:00 amRNSUpdate on Taiwan laboratory disposal
1st Dec 202311:45 amRNSLiquidity Agreement and Total Voting Rights
7th Nov 20237:00 amRNSIVDR certification for DPYD genotyping assay
1st Nov 20232:30 pmRNSLiquidity Agreement and Total Voting Rights
26th Oct 20233:20 pmRNSResult of AGM
11th Oct 20237:00 amRNSAGM voting
5th Oct 20232:15 pmRNSNotice of rescheduled AGM
2nd Oct 20231:30 pmRNSLiquidity Agreement and Total Voting Rights
28th Sep 20233:15 pmRNSReminder to shareholders re. AGM voting
28th Sep 20237:00 amRNS2023 Interim Results
14th Sep 20237:00 amRNSAGM voting
13th Sep 20237:00 amRNSNotice of Results
11th Sep 20237:55 amRNSCancellation of trading of Yourgene Shares
8th Sep 202312:00 pmRNSCompletion of acquisition of Yourgene Health plc
8th Sep 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
7th Sep 202312:22 pmRNSCourt sanction of the Scheme of Arrangement
1st Sep 202312:30 pmRNSLiquidity Agreement and Total Voting Rights
29th Aug 20237:00 amRNSNotice of rescheduled AGM
17th Aug 20235:16 pmRNSAcquisition update
1st Aug 202311:45 amRNSLiquidity Agreement and Total Voting Rights
27th Jul 20237:00 amRNSHalf Year Trading Update
19th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
18th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
17th Jul 202312:00 pmRNSForm 8.5 (EPT/RI)
14th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
13th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
13th Jul 20237:00 amRNSNotice of cancelled AGM
12th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
11th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
10th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
7th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
6th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
5th Jul 20231:27 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc Amended
5th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
4th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
3rd Jul 202312:00 pmRNSLiquidity Agreement and Total Voting Rights
3rd Jul 20237:01 amRNSRecommended cash offer for Yourgene Health plc
15th Jun 20234:00 pmRNSNotice of rescheduled AGM
12th Jun 20237:00 amRNSReminder to shareholders re. AGM voting
1st Jun 20231:00 pmRNSLiquidity Agreement and Total Voting Rights
26th May 20237:00 amRNSPublication of Annual Report and AGM voting
10th May 20237:00 amRNSNotice of AGM
2nd May 202312:30 pmRNSTotal Voting Rights
27th Apr 20237:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.